Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH +3.40%80 Graham Number is $22.41 as of Mar. 2026, which is 460% above its 10-year median of 4.00. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $90.62 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 604 Drug Manufacturers companies, Lantheus Holdings ranks worse than 90.89% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-22), the stock price of Lantheus Holdings is $107.96. Lantheus Holdings's graham number for the quarter that ended in Mar. 2026 was $22.41. Therefore, Lantheus Holdings's Price to Graham Number ratio for today is 4.82.
The historical rank and industry rank for Lantheus Holdings's Graham Number or its related term are showing as below:
LNTH'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.75 Med: 4 Max: 24.46
Current: 4.81
During the past 13 years, the highest Price to Graham Number ratio of Lantheus Holdings was 24.46. The lowest was 1.75. And the median was 4.00.
LNTH's Price-to-Graham-Number is ranked worse than 90.89% of 604
companies
in the Drug Manufacturers industry
Industry Median: 1.52
vs LNTH: 4.81
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Lantheus Holdings (NAS:LNTH) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Lantheus Holdings's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
107.96
/
22.41
=
4.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Lantheus Holdings Graham Number Related Terms
Lantheus Holdings Graham Number Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs LQDA, HIMS, AMRX: Graham Number Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Price-to-Graham-Number vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings (LNTH) has a Graham Number of $22.41 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Lantheus Holdings and its competitors. This is 460% above median its historical median of 4.00. Over the past decade, Lantheus Holdings' Graham Number has ranged from 1.75 to 24.46. According to the industry distribution chart, Lantheus Holdings ranks #549 out of 604 companies in the Drug Manufacturers industry, placing it in the top 90.9%.
Is Lantheus Holdings' Graham Number too high?
Lantheus Holdings' current Graham Number of $22.41 is 460% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 24.46. The Drug Manufacturers industry median Graham Number is 1.52. Lantheus Holdings' value of $22.41 is 1374.3% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #549 out of 604 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Graham Number compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #549 out of 604 companies for Graham Number. This places Lantheus Holdings in the lower half of its industry. The industry median Graham Number is 1.52. Lantheus Holdings' value of $22.41 is 1374.3% above this benchmark. Historically, Lantheus Holdings' own Graham Number has ranged from 1.75 to 24.46 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 1.52, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Drug Manufacturers company?
The median Graham Number among Drug Manufacturers companies is 1.52, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Graham Number of $22.41 is 1374.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Graham Number is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Graham Number is $22.41, which is 460% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.62, compared to a current price of $107.96 — trading 19.1% above its estimated fair value. The current Graham Number is $22.41, which is 460% above median its 10-year median of 4.00 and 1374.3% above the Drug Manufacturers industry median of 1.52. Lantheus Holdings' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Graham Number is $22.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $107.96 is trading 19.1% above its estimated GF Value™ of $90.62.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Graham Number: $22.41 (460% above median its 10-year median of 4.00)
GF Value™: $90.62 vs. price of $107.96 (19.1% above fair value)
Industry Position: 1374.3% above the Drug Manufacturers median (#549 of 604)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
